Nasdaq:US$8.74 (-0.42) | HKEX:HK$13.80 (+0.28) | AIM:£1.59 (-0.08)
About Us

HUTCHMED is  an innovative, commercial-stage biopharmaceutical company committed to the discovery and global development of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases.

We are among the first global-focused novel drug discovery companies in China. Over the past two decades, we have established a fully integrated R&D platform with world-class discovery and development capabilities. Since inception we have advanced 13 cancer drug candidates from in-house discovery into clinical studies around the world, with our first three oncology drugs now approved and marketed.

We have also developed a profitable commercial platform with deep pan-China market access, which manufactures, markets and distributes our novel oncology products, as well as prescription drugs and consumer health products in China. We are expanding the geographic scope of our commercial operations to include the U.S. and Europe.

HUTCHMED is listed on the Nasdaq Global Select Market, the Stock Exchange of Hong Kong Limited and the London Stock Exchange’s AIM market (Nasdaq/AIM:HCM; HKEX:13).

2000
FOUNDED
HCM
NASDAQ &
LONDON AIM
13
HKEX
13
IN-HOUSE DISCOVERED
CLINICAL STAGE CANCER
DRUG CANDIDATES
3
APPROVED & MARKETED
PRODUCTS IN CHINA
1
IN-LICENSED PRODUCT
LAUNCHED IN CHINA
HAINAN PILOT ZONE
~40
CLINICAL TRIALS WORLDWIDE
INCLUDING 13 REGISTRATION STUDIES
4,900
PERSONNEL ACROSS
THE GROUP